checkAd

     151  0 Kommentare Diffusion Pharmaceuticals Receives European Patent Related Compositions of TSC - Seite 3

    Contacts:
    David Kalergis, CEO
    Diffusion Pharmaceuticals Inc.
    (434) 220-0718
    dkalergis@diffusionpharma.com
    or
    LHA Investor Relations
    Kim Sutton Golodetz
    (212) 838-3777
    kgolodetz@lhai.com

    Lesen Sie auch


    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3
    Verfasst von globenewswire
    Diffusion Pharmaceuticals Receives European Patent Related Compositions of TSC - Seite 3 CHARLOTTESVILLE, Va., Feb. 07, 2020 (GLOBE NEWSWIRE) - Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by …